Estamos no ar no ! Saiba mais
DMK

DMK Pharmaceuticals Corporation Common Stock
DMK

Deslistada

DMK foi retirado da bolsa em 6 de fevereiro de 2024.

Voltar ao ranking
 

Sobre: DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Funcionários: 12

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 0%
Neutro 0%
Negativo 0%
Neutro
Newsfile Corp
há 2 anos
DMK Pharmaceuticals Commences Restructuring Proceeding
San Diego, California--(Newsfile Corp. - February 2, 2024) - DMK Pharmaceuticals Corporation (NASDAQ: DMK) ("DMK" or the "Company"), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, and certain of its direct and indirect subsidiaries (collectively, the "Company Parties") today (the "Petition Date") commenced bankruptcy cases (the "Chapter 11 Cases") by filing voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On the Petition Date, the Company Parties filed a motion with the Bankruptcy Court seeking to jointly administer the Chapter 11 Cases under the caption "In re: DMK Pharmaceuticals Corporation, et al.
DMK Pharmaceuticals Commences Restructuring Proceeding
Neutro
GlobeNewsWire
há 2 anos
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
Neutro
GlobeNewsWire
há 2 anos
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI® and ZIMHI® (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
Neutro
GlobeNewsWire
há 2 anos
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI ® and thus increase shareholder value
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™